Evidence map›Paper›PMID 39639913›Full record

ArticleFrontiers in public health2024

Rapid methods for multi-level dissemination of neutralizing monoclonal antibody treatment for COVID-19 outpatients: designing for dissemination using the fit to context framework.

Bethany M Kwan, Chelsea Sobczak, Lindsey E Fish, Adit A Ginde, Gillian Grant, Mika K Hamer, Kyle Leggott, Vanessa Owen, Jenna Reno, Justin Shrader and 6 more

Abstract read
In one paragraph

Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Bethany M KwanDepartment of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, United States.
Chelsea SobczakDepartment of Family Medicine, University of Colorado School of Medicine, Aurora, CO, United States.
Lindsey E FishDepartment of General Internal Medicine, Denver Health and Hospital, Denver, CO, United States.
Adit A GindeDepartment of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, United States.
Gillian GrantTrailhead Institute, Denver, CO, United States.
Mika K HamerCenter for Bioethics and Humanities, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Kyle LeggottDepartment of Family Medicine, University of Colorado School of Medicine, Aurora, CO, United States.
Vanessa OwenDepartment of Family Medicine, University of Colorado School of Medicine, Aurora, CO, United States.
Jenna RenoDepartment of Family Medicine, University of Colorado School of Medicine, Aurora, CO, United States.
Justin ShraderColorado Clinical & Translational Sciences Institute, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Lindsey WhittingtonColorado Health Institute, Denver, CO, United States.
Jenn L JonesColorado Clinical & Translational Sciences Institute, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Ramona KorenAdvisory Panel Member.
Joel A BegayAdvisory Panel Member.
Vall VinaithirthanDivision of General Internal Medicine, University of Colorado School of Medicine, Aurora, CO, United States.
Hillary D LumDivision of Geriatric Medicine, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, United States.

Funding

NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1M
Colorado Clinical and Translational Sciences Institute (CCTSI)UM1TR004399 · NCATS · UNIVERSITY OF COLORADO DENVER · PI JANINE A HIGGINS, RONALD J. SOKOL · 2023 to 2026
$30.7M
NCATS NIH HHS L40 TR002525NCATS NIH HHS UL1 TR002535NCATS NIH HHS UM1 TR004399
6 · The paper itself

Abstract

Introduction: Throughout the COVID-19 pandemic, there was an urgent need for the rapid and equitable translation of knowledge and effective treatments to reach vulnerable populations in response to the ever-shifting pandemic environment. The approval of neutralizing monoclonal antibodies (mAbs) for treatment of outpatient COVID-19 resulted in a need to rapidly design dissemination strategies to increase awareness and equitable access for community members and healthcare providers. Materials and methods: We used the Fit to Context (F2C) Framework for Designing for Dissemination and Sustainability to (a) design products such as messages and materials, and (b) disseminate the products. We leveraged existing partnerships (e.g., community members, health system leaders, Regional Health Connectors, public health agencies, policymakers, and others) for activities including (a) advising on contextual implementation challenges and opportunities; (b) convening a stakeholder advisory panel; (c) rapid feedback on product reach and impact; and (d) serving as potential product adopters and distributors. We used concurrent data collection and co-design with rapid, iterative prototyping. We used real-world data to evaluate impact of D&I strategies on mAb use in Colorado. Results: Moving through the F2C Framework phases, we assessed mAb implementation and access barriers and facilitators, identified partner priorities, co-designed messages and materials for multiple audiences, and disseminated through audience-specific communication channels. An emphasis on equity led to tailoring materials to communities with lower health literacy, under- and uninsured groups, Spanish-speaking communities, Native American communities, and rural areas. Dissemination messages, materials, and distribution strategies were updated frequently based on emerging data on COVID-19 treatment effectiveness and availability. Real-world data revealed more than 400% increase in both referrals and number of unique referring providers, with the greatest impact on underserved communities. This was accomplished in under 9 months. Conclusion: The Fit to Context Framework for Designing for Dissemination and Sustainability is a novel process framework that can inform a rapid, iterative dissemination strategy. The COVID-19 pandemic presented an opportunity to learn better ways to speed translation of evidence to practice and enhance equitable access to evidence-based care. The mAb Colorado project demonstrated the importance of having strong community-academic-public health partnerships and leveraging existing capacity to enhance adoption and reach.

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingCOVID-19SARS-CoV-2COVID-19 Drug TreatmentHumansInformation DisseminationOutpatientsAntibodies, MonoclonalAntibodies, Neutralizingcommunity engagementCOVID-19designing for disseminationmonoclonal antibody treatmentparticipatory co-designrapid research methods

Identifiers

PMID39639913
PMCPMC11617208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.